Home / Business and Economy / Guardant Health Soars: Q2 Revenue Jumps 44%
Guardant Health Soars: Q2 Revenue Jumps 44%
1 Aug
Summary
- Guardant Health's Q2 revenue reached $335 million, a 44% increase year-over-year.
- New Guardant360 Liquid CDx test received FDA approval, offering expanded genomic content.
- Expected Advanced Diagnostic Laboratory Test (ADLT) price of $8,455 could significantly increase reimbursement.
Guardant Health achieved substantial growth in the second quarter of 2026, reporting revenue of $335 million, a remarkable 44% increase compared to the previous year. This acceleration was propelled by strong performance across its oncology, biopharma, and data, and screening divisions. The company has consequently revised its full-year revenue projections upward, citing robust demand for its Guardant360 and Shield products, alongside key regulatory achievements and expanded reimbursement access.
Key to this success is the recent FDA approval of Guardant360 Liquid CDx. This advanced liquid biopsy panel integrates extensive genomic and epigenomic information, significantly surpassing its predecessor. The company has commenced a phased U.S. rollout, anticipating broader availability in the first half of 2027. Furthermore, the projected Advanced Diagnostic Laboratory Test (ADLT) price of $8,455 is substantially higher than the current Medicare rate, signaling a potential major uplift in future revenue, though payer adjustments may take 12 to 24 months.
